DOCBACTAM 1500MG

Indications

• Bacterial meningitis
• Community-acquired pneumonia
• Intra-abdominal infections
• Skin and soft tissue infections
• Urinary tract infections
• Septicemia
• Pelvic inflammatory disease

Dosage

Children: Refer to the BNF for Children for specific dosing guidelines based on the age and weight of the child.

Adults: Refer to the BNF for specific dosing guidelines based on the indication and severity of infection.

Mechanism of action

Ceftriaxone works by inhibiting bacterial cell wall synthesis through binding to penicillin-binding proteins (PBPs). This inhibition disrupts the transpeptidation process, which is crucial for cross-linking peptidoglycan layers in the bacterial cell wall, leading to cell lysis and death.

Pharmacodynamics

The pharmacodynamics of ceftriaxone demonstrates a time-dependent bactericidal effect. The drug's activity is influenced by its concentration in the body and the time it remains above the minimum inhibitory concentration (MIC) for the target pathogens. Ceftriaxone is effective against a wide range of organisms, including Streptococcus pneumoniae, Escherichia coli, and Neisseria gonorrhoeae.

Pharmacokinetics

Ceftriaxone is administered intravenously or intramuscularly and is widely distributed throughout the body, including in the central nervous system. It has a long half-life of approximately 6 to 8 hours, allowing for once-daily dosing in many cases. The drug is primarily eliminated via the kidneys, with about 50-60% excreted unchanged in the urine, and the remainder being metabolized in the liver.

Contra-indications

• Hypersensitivity to ceftazidime or to any other cephalosporin antibiotic
• History of severe allergic reactions to penicillins or other beta-lactam antibiotics

Adverse effects

• Diarrhea
• Nausea
• Vomiting
• Rash
• Urticaria
• Anaphylaxis
• Superinfection
• Hematologic reactions such as thrombocytopenia or leukopenia
• Elevated liver enzymes

Interactions

• Probenecid may increase ceftazidime levels by reducing renal excretion
• Other nephrotoxic drugs may increase the risk of renal toxicity
• Anticoagulants may have an increased risk of bleeding

Precautions

• Use with caution in patients with renal impairment
• Monitor renal function during therapy
• May cause Clostridium difficile-associated diarrhea
• Use cautiously in patients with a history of gastrointestinal disease

Pregnancy

Ceftazidime is classified as pregnancy category B. Animal studies have not shown any harm to the fetus, but there are no well-controlled studies in pregnant women. Use only if clearly needed.

Breast-feeding

Ceftazidime is excreted in breast milk in small amounts. Caution is advised when administering to nursing mothers.

Storage

Store at 20-25 degrees Celsius. Protect from light and moisture. After reconstitution, use within specified time frames as indicated in product labeling.

Formulations

• Injection: 1 g and 2 g vials for intravenous or intramuscular use
• Reconstituted solution for injection

Indications

• Infections caused by beta-lactamase producing organisms
• Complicated skin and soft tissue infections
• Intra-abdominal infections
• Respiratory tract infections
• Urinary tract infections

Dosage

Children: Refer to BNF for Children for specific dosing recommendations based on the child's age, weight, and the type of infection.

Adults: Refer to BNF for specific dosing recommendations based on the type and severity of the infection.

Mechanism of action

Sulbactam is a competitive, irreversible inhibitor of bacterial beta-lactamases, particularly potent against class C beta-lactamases. It binds to the active site of the enzyme, preventing it from hydrolyzing beta-lactam antibiotics, which enhances the effectiveness of these antibiotics against resistant bacterial strains.

Pharmacodynamics

When administered with beta-lactam antibiotics, sulbactam broadens their antibacterial spectrum by inhibiting the enzymes responsible for their hydrolysis. Although sulbactam has weak intrinsic antibacterial activity on its own, it can effectively bind to penicillin-binding proteins in certain bacteria, contributing to its therapeutic effect. It helps restore the activity of beta-lactam antibiotics against a wide range of beta-lactamase-producing gram-positive and gram-negative bacteria.

Pharmacokinetics

Sulbactam is administered parenterally and is typically well absorbed. It has a short half-life, necessitating frequent dosing when used alone. The drug is primarily excreted unchanged in the urine. Its pharmacokinetic profile may vary based on the formulation used and the presence of co-administered antibiotics.

Pregnancy

There is limited data on the use of sulbactam in pregnancy. It should only be used if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

It is not known if sulbactam is excreted in human milk. Caution is advised when administering to breastfeeding women.

Storage

Store in a cool, dry place, away from direct light. Protect from moisture.

Formulations

• Injectable solution

Mechanism of action

Sulbactam is a competitive, irreversible bacterial beta (β)-lactamase inhibitor. It is reported to be more potent against class C beta-lactamases.

Pharmacodynamics

When given together with beta-lactam antibiotics, sulbactam broadens their antibacterial spectrum by blocking the enzyme involved in their hydrolysis. Sulbactam alone possesses weak intrinsic antibacterial activity except against the _Neisseriaceae_, _Acinetobacter spp._, and _Bacteroides fragilis_ as it can bind to the penicillin-binding proteins. Sulbactam restores the activity of beta-lactam antibiotics against a range of beta-lactamase-producing gram-positive and gram-negative bacteria.